A Phase 2 interventional study of Pertuzumab and Trastuzumab in Metastatic Breast Cancer, sponsored by Genentech, Inc.. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-07.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies testing pertuzumab in Breast Neoplasms — 26 open to participants now, 45 under way, 7 of them phase 3. pertuzumab · Breast Neoplasms.
Among the 104 studies testing pertuzumab in Breast Neoplasms, this one is the 84th largest by enrollment, is one of 8 that started in 2015, is one of 59 in phase 2, and was the 38th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →26 of the 104 studies testing pertuzumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:
Wen-Ming Cao · Sites in China
Ages 60+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Alliance for Clinical Trials in Oncology · Sites in United States, Puerto Rico
Ages 18+
By country, each count listing its studies:
pertuzumab: first FDA approval 2012 (PERJETA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pertuzumab is the treatment under test here. Read study by study →
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 63 · Phase 3 23 · Phase 4 3
First in 2003; this study’s year is marked. 8 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 100 across the 104 interventional studies. Of the 50 that completed or were terminated, 34 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 104 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 143rd largest by enrollment of the 170 interventional ones that give a count, is one of 20 that started in 2015, is one of 65 in phase 2, and was the 150th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
10 of the studies testing pertuzumab in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07187752Shandong Cancer Hospital and InstituteIdentification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes | 2026-12-31 |
| NCT04733118MedSIRChemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 104 studies testing pertuzumab in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will examine the safety and efficacy of pertuzumab in combination with high-dose trastuzumab in adult participants with HER2-positive MBC with CNS metastases and disease progression in the brain following radiotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with CNS metastases secondary to HER2-positive MBC will receive pertuzumab in combination with high-dose trastuzumab until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Drug: Pertuzumab · Drug: Trastuzumab
Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Also known as: Perjeta, RO4368451
Participants will receive trastuzumab at a dose of 6 milligrams per kilogram (mg/kg) of body weight once weekly via IV infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Also known as: Herceptin, RO0452317
Percentage of Participants With Objective Response in the CNS, Assessed Using Response Assessment in Neuro-Oncology-Brain Metastases (RANO-BM) Criteria
Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. An objective response in the central nervous system (CNS) was a complete response (CR) or partial response (PR) confirmed by repeat assessment, according to RANO-BM criteria. A CR was defined as the disappearance of all CNS target lesions sustained for at least 4 weeks; no new lesions; no corticosteroids; and stable or improved clinically; for non-target lesions, a CR was the disappearance of all enhancing CNS non-target lesions and no new CNS lesions. A PR was defined as at least a 30% decrease in the sum longest diameter (LD) of CNS target lesions, taking as reference the baseline sum LD sustained for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; and stable or improved clinically. The 95% Clopper-Pearson exact confidence intervals were calculated for responses.
Time frame: From Baseline until disease progression (assessed every 6 weeks for first 2 scans, followed by every 8 weeks for 2 scans, then every 12 weeks until disease progression; up to approximately 3.5 years)
Median Duration of Response in the CNS, Assessed Using RANO-BM Criteria
Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. An objective response in the central nervous system (CNS) was a complete response (CR) or partial response (PR) confirmed by repeat assessment, according to RANO-BM criteria. Among participants who achieved an objective response, duration of response in the CNS was defined as the time from documentation of the first CR or PR to the time of disease progression, relapse, or death from any cause. If a participant did not experience death or disease progression in the CNS before the end of the study, duration of response was censored on the last date the participant was known to be progression free. Duration of response was estimated by the Kaplan-Meier method.
Time frame: From documentation of first complete response (CR) or partial response (PR) to the time of disease progression, relapse, or death from any cause, whichever occurred first (up to approximately 3.5 years)
Percentage of Participants With Clinical Benefit (Confirmed CR, PR, or Stable Disease [SD] ≥4 Months) in the CNS, Assessed Using RANO-BM Criteria
Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. Clinical benefit in the central nervous system (CNS) was defined here as a complete response (CR), partial response (PR), or stable disease (SD) for at least 4 months, confirmed by repeat assessment according to RANO-BM criteria. A CR or PR were defined in the same way as for objective response in the CNS. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter (LD) while on study. The 95% Clopper-Pearson exact confidence intervals were calculated for responses.
Time frame: From Baseline until disease progression (assessed every 6 weeks for first 2 scans, followed by every 8 weeks for 2 scans, then every 12 weeks until disease progression; up to approximately 5 years)
Median Duration of Clinical Benefit (Confirmed CR, PR, or SD ≥4 Months) in the CNS, Assessed Using RANO-BM Criteria
Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. Clinical benefit in the central nervous system (CNS) was defined here as a complete response (CR), partial response (PR), or stable disease (SD) for at least 4 months, confirmed by repeat assessment according to RANO-BM criteria. Among participants who achieved clinical benefit, duration of clinical benefit in the CNS was defined as the time from documentation of the first CR, PR, or SD ≥4 months to the time of disease progression, relapse, or death from any cause. If a participant did not experience death or disease progression in the CNS before the end of the study, duration of clinical benefit was censored on the last date the participant was known to be progression free. Duration of clinical benefit was estimated by the Kaplan-Meier method.
Time frame: From documentation of first complete response (CR), partial response (PR), or stable disease (SD) ≥4 months to the date of disease progression, relapse, or death from any cause, whichever occurred first (up to approximately 5 years)
Percentage of Participants With Clinical Benefit (Confirmed CR, PR, or SD ≥6 Months) in the CNS, Assessed Using RANO-BM Criteria
Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. Clinical benefit in the central nervous system (CNS) was defined here as a complete response (CR), partial response (PR), or stable disease (SD) for at least 6 months, confirmed by repeat assessment according to RANO-BM criteria. A CR or PR were defined in the same way as for objective response in the CNS. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter (LD) while on study. The 95% Clopper-Pearson exact confidence intervals were calculated for responses.
Time frame: From Baseline until disease progression (assessed every 6 weeks for first 2 scans, followed by every 8 weeks for 2 scans, then every 12 weeks until disease progression; up to approximately 5 years)
Median Duration of Clinical Benefit (Confirmed CR, PR, or SD ≥6 Months) in the CNS, Assessed Using RANO-BM Criteria
Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. Clinical benefit in the central nervous system (CNS) was defined here as a complete response (CR), partial response (PR), or stable disease (SD) for at least 6 months, confirmed by repeat assessment according to RANO-BM criteria. Among participants who achieved clinical benefit, duration of clinical benefit in the CNS was defined as the time from documentation of the first CR, PR, or SD ≥6 months to the time of disease progression, relapse, or death from any cause. If a participant did not experience death or disease progression in the CNS before the end of the study, duration of clinical benefit was censored on the last date the participant was known to be progression free. Duration of clinical benefit was estimated by the Kaplan-Meier method.
Time frame: From documentation of first complete response (CR), partial response (PR), or stable disease (SD) ≥6 months to the date of disease progression, relapse, or death from any cause, whichever occurred first (up to approximately 5 years)
Progression-Free Survival (CNS), Assessed Using RANO-BM Criteria
Progression-free survival (CNS) was defined as the time from the date of first dose to disease progression in the CNS or death from any cause. If no progressive disease in the CNS and no death occurred, progression-free survival (CNS) was censored on the date of the last CNS tumor assessment. If a post-baseline assessment was not available, progression-free survival (CNS) was censored on Day 1.
Time frame: From the date of first dose to disease progression in the CNS or death from any cause, whichever occurred first (up to approximately 5 years)
Progression-Free Survival (Systemic), Assessed Using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
Progression-free survival (systemic) was defined as the time from the date of first dose to systemic disease progression or death from any cause. If no systemic disease progression and no death occurred, progression-free survival (systemic) was censored on the date of the last systemic tumor assessment. If a post-baseline assessment was not available, progression-free survival (systemic) was censored on Day 1.
Time frame: From the date of first dose to systemic disease progression or death from any cause, whichever occurred first (up to approximately 5 years)
Progression-Free Survival (CNS or Systemic), Assessed Using RANO-BM Criteria and RECIST v1.1
Progression-free survival (CNS or systemic) was defined as the time from the date of first dose to CNS or systemic disease progression or death from any cause. If no CNS or systemic disease progression and no death occurred, data was censored on the date of the last CNS or systemic tumor assessment, whichever occurred first. If a post-baseline assessment was not available, data was censored on Day 1.
Time frame: From the date of first dose to CNS or systemic disease progression or death from any cause, whichever occurred first (up to approximately 5 years)
Overall Survival
Overall survival was defined as the period from the date of first dose until the date of death from any cause. If no death occurred, overall survival was censored on the last date the participant was known to be alive.
Time frame: From the date of first dose until death due to any cause (up to approximately 5 years)
Number of Deaths by Time (≤30 or >30 Days) From Last Study Drug Administration and by Primary Cause of Death
Time frame: From date of first dose until death due to any cause (up to approximately 5 years)
Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) by Highest Grade of Severity, According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0)
Treatment-emergent adverse events (TEAEs) were defined as all adverse events occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment. All TEAEs were graded for severity using the NCI-CTCAE v4.0; any TEAE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to adverse event. Multiple occurrences of TEAEs were counted only once per participant at the highest (worst) grade.
Time frame: From the first dose until 30 days after the last dose of study treatment (up to approximately 5 years)
Number of Participants With at Least One Treatment-Emergent Serious Adverse Event (SAE) by Highest Grade of Severity, According to NCI-CTCAE v4.0
Treatment-emergent serious adverse events (SAEs) were defined as all adverse events that met seriousness criteria (as defined in the protocol; same as the ClinicalTrials.gov definition) occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment. All SAEs were graded for severity using the NCI-CTCAE v4.0; any SAE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe or medically significant, but not immediately life-threatening; Grade 4 = life-threatening consequences or urgent intervention indicated; and Grade 5 = death related to adverse event. The terms "severe" and "serious" are not synonymous and are independently assessed for each adverse event. Multiple occurrences of SAEs were counted only once per participant at the highest (worst) grade.
Time frame: From the first dose until 30 days after the last dose of study treatment (up to approximately 5 years)
Number of Participants With at Least One TEAE Leading to Withdrawal of Any Study Drug, Pertuzumab Only, or Both Pertuzumab and Trastuzumab, by Highest Grade of Severity According to NCI-CTCAE v4.0
Treatment-emergent adverse events (TEAEs) were defined as all adverse events occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment. All TEAEs were graded for severity using the NCI-CTCAE v4.0; any TEAE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to adverse event. Multiple occurrences of TEAEs were counted only once per participant at the highest (worst) grade.
Time frame: From the first dose until 30 days after the last dose of study treatment (up to approximately 5 years)
Number of Participants With at Least One TEAE Leading to Pertuzumab Infusion Delay, Slow Down, or Interruption, by Highest Grade of Severity According to NCI-CTCAE v4.0
Treatment-emergent adverse events (TEAEs) were defined as all adverse events occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment. All TEAEs were graded for severity using the NCI-CTCAE v4.0; any TEAE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to adverse event. Multiple occurrences of TEAEs were counted only once per participant at the highest (worst) grade.
Time frame: From the first dose until 30 days after the last dose of study treatment (up to approximately 5 years)
Number of Participants With at Least One TEAE Leading to Trastuzumab Dose Modification by Highest Grade of Severity According to NCI-CTCAE v4.0
Treatment-emergent adverse events (TEAEs) were defined as all adverse events occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment. All TEAEs were graded for severity using the NCI-CTCAE v4.0; any TEAE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to adverse event. Multiple occurrences of TEAEs were counted only once per participant at the highest (worst) grade.
Time frame: From the first dose until 30 days after the last dose of study treatment (up to approximately 5 years)
Percentage of Participants With at Least One TEAE of Special Interest by Highest Grade of Severity, According to NCI-CTCAE v4.0
Protocol-defined TEAEs of special interest, occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment, included the following: An elevated ALT or AST (\>3 times baseline value) in combination with either an elevated total bilirubin (\>2 times the upper limit of normal) or clinical jaundice; Suspected transmission of an infectious agent by the study treatment; Congestive heart failure; An asymptomatic decline in LVEF (a value 10 percentage points below baseline or lower, and \<45%) that requires treatment or that leads to discontinuation of study treatment. All TEAEs of special interest were graded for severity using the NCI-CTCAE v4.0. Multiple occurrences of TEAEs of special interest were counted only once per participant at the highest (worst) grade.
Time frame: From the first dose until 30 days after the last dose of study treatment (up to approximately 5 years)
Median Left Ventricular Ejection Fraction (LVEF) Values Over Time
Left ventricular ejection fraction (LVEF) is the measurement of the percentage of blood that is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. All participants were required to have had a baseline LVEF of at least 50% to participate in this study. Measurements were done by either echocardiogram (ECHO) or mulitple-gated acquisition (MUGA) scan (with ECHO as the preferred method). Participants were to be reassessed with the same technique used for baseline cardiac evaluation throughout the study.
Time frame: Baseline, Weeks 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132 (Treatment Period); and every 3 months during Survival Follow-Up (up to approximately 5 years)
Number of Participants by Investigator Interpretation of Left Ventricular Ejection Fraction (LVEF) Assessments Over Time
Left ventricular ejection fraction (LVEF) is the measurement of the percentage of blood that is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. All participants were required to have had a baseline LVEF of at least (≥)50% to participate in this study. Measurements were done by either echocardiogram (ECHO) or mulitple-gated acquisition (MUGA) scan (with ECHO as the preferred method). Participants were to be reassessed with the same technique used for baseline cardiac evaluation throughout the study. The following are definitions for the three categories of LVEF findings: 'Normal' was defined as LVEF \>45% or LVEF 40-45% with less than (\<)10% points drop below baseline; 'Abnormal' was defined as LVEF \<40% or LVEF ≥10% points drop below baseline, and clinically significant versus non-clinically significant was subject to the investigator's assessment of whether symptoms were present or absent.
Time frame: Baseline, Weeks 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132 (Treatment Period); and every 3 months during Survival Follow-Up (up to approximately 5 years)
Number of Participants With NCI-CTCAE v4.0 Grades 3 and 4 Clinical Laboratory Abnormalities in Hematology Tests Over Time
Clinical laboratory tests for hematology parameters were performed every 6 weeks and any abnormal values (High or Low) were based on NCI-CTCAE v4.0 grades. Laboratory abnormalities of NCI-CTCAE v4.0 Grades 3 and 4 are presented. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. For the overall category, multiple occurrences of the same laboratory abnormality over time in one participant were only counted once.
Time frame: Baseline, Weeks 18, 36, and 60 (up to approximately 5 years)
Number of Participants With NCI-CTCAE v4.0 Grades 3 and 4 Clinical Laboratory Abnormalities in Blood Chemistry Tests Over Time
Clinical laboratory tests for blood chemistry parameters were performed every 6 weeks and any abnormal values (High or Low) were based on NCI-CTCAE v4.0 grades. Laboratory abnormalities of NCI-CTCAE v4.0 Grades 3 and 4 are presented. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. For the overall category, multiple occurrences of the same laboratory abnormality over time in one participant were only counted once.
Time frame: Weeks 6, 12, and 18, and Unscheduled Visits (up to approximately 5 years)
Observed Trough Serum Concentrations (Cmin) of Pertuzumab at Specified Timepoints
Per protocol eligibility criteria, participants were not required to be pertuzumab naïve; therefore pertuzumab was detectable in some participants pre-dose at Week 1.
Time frame: Pre-dose (0-4 hours) on Day 1 of Weeks 1, 4, 10, and 16
Maximum Serum Concentrations (Cmax) of Pertuzumab at Specified Timepoints
Time frame: Post-infusion (0-30 minutes, infused over 60 minutes) on Day 1 of Week 1 and 16
Observed Trough Serum Concentrations (Cmin) of Trastuzumab at Specified Timepoints
Per protocol eligibility criteria, participants were not required to be trastuzumab naïve; therefore trastuzumab was detectable in some participants pre-dose at Week 1.
Time frame: Pre-dose (0-4 hours) on Day 1 of Weeks 1, 4, 10, and 16
Maximum Serum Concentrations (Cmax) of Trastuzumab at Specified Timepoints
Time frame: Post-infusion (0-30 minutes, infused over 60 minutes) on Day 1 of Week 1 and 16
Symptom Severity Scale Score Over Time, Assessed by Participant Reporting on the M.D. Anderson Symptom Inventory-Brain Tumor (MDASI-BT) Questionnaire
The MDASI-BT consists of 28 items and is a multi-symptom measure of cancer-related symptoms (Cleeland et al. 2000) that are sensitive to disease and treatment changes. The MDASI-BT is composed of the symptom severity scale and the symptom interference scale. In the symptom severity scale, participants rate the severity of their symptoms in the last 24 hours on 0-10 numeric scales, ranging from 0 = "not present" to 10 = "as bad as you can imagine." The MDASI-BT symptom severity scale score will be calculated by (sum of total scores of non-missing items) divided by (total number of non-missing items), if participants answered at least 12 of the 22 severity scale items. The score will be considered missing if less than 12 items are completed.
Time frame: Baseline, Weeks 6, 12, 20, 28, 40, 52, and 64
Symptom Interference Scale Score Over Time, Assessed by Participant Reporting on the MDASI-BT Questionnaire
The MDASI-BT consists of 28 items and is a multi-symptom measure of cancer-related symptoms that are sensitive to disease and treatment changes. The MDASI-BT is composed of the symptom severity scale and the symptom interference scale. In the symptom interference scale, participants rate interference with daily activities caused by their symptoms on 0-10 numeric scales ranging from 0 = "did not interfere" to 10 = "interfered completely." The MDASI-BT symptom interference scale score will be calculated by (sum of total scores of non-missing items) divided by (total number of non-missing items), if participants answered at least 4 of the 6 interference scale items. The score will be considered missing if less than 4 items are completed.
Time frame: Baseline, Weeks 6, 12, 20, 28, 40, 52, and 64
| Milestone | Pertuzumab + Trastuzumab |
|---|---|
| Started | 40 |
| Received at least one dose of study drug | 39 |
| Efficacy-evaluable population | 37 |
| Completed | 12 |
| Not completed | 28 |
| Withdrew: Death | 20 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Treatment discontinued | 2 |
| Withdrew: Physician decision | 1 |
Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. An objective response in the central nervous system (CNS) was a complete response (CR) or partial response (PR) confirmed by repeat assessment, according to RANO-BM criteria. A CR was defined as the disappearance of all CNS target lesions sustained for at least 4 weeks; no new lesions; no corticosteroids; and stable or improved clinically; for non-target lesions, a CR was the disappearance of all enhancing CNS non-target lesions and no new CNS lesions. A PR was defined as at least a 30% decrease in the sum longest diameter (LD) of CNS target lesions, taking as reference the baseline sum LD sustained for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; and stable or improved clinically. The 95% Clopper-Pearson exact confidence intervals were calculated for responses.
| Percentage of Participants | Pertuzumab + Trastuzumab |
|---|---|
| With Objective Response (Confirmed CR or PR) | 10.8 (3.03 to 25.42) |
| Confirmed Complete Response (CR) | 0.0 (0.00 to 9.49) |
| Confirmed Partial Response (PR) | 10.8 (3.03 to 25.42) |
| Without Objective Response | 89.2 (NA to NA) |
Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. An objective response in the central nervous system (CNS) was a complete response (CR) or partial response (PR) confirmed by repeat assessment, according to RANO-BM criteria. Among participants who achieved an objective response, duration of response in the CNS was defined as the time from documentation of the first CR or PR to the time of disease progression, relapse, or death from any cause. If a participant did not experience death or disease progression in the CNS before the end of the study, duration of response was censored on the last date the participant was known to be progression free. Duration of response was estimated by the Kaplan-Meier method.
| Months | Pertuzumab + Trastuzumab |
|---|---|
| Median Duration of Response in the CNS, Assessed Using RANO-BM Criteria | 4.60 (3.19 to 5.59) |
Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. Clinical benefit in the central nervous system (CNS) was defined here as a complete response (CR), partial response (PR), or stable disease (SD) for at least 4 months, confirmed by repeat assessment according to RANO-BM criteria. A CR or PR were defined in the same way as for objective response in the CNS. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter (LD) while on study. The 95% Clopper-Pearson exact confidence intervals were calculated for responses.
| Percentage of Participants | Pertuzumab + Trastuzumab |
|---|---|
| With Clinical Benefit (Confirmed CR,PR,or SD≥4mos) | 67.6 (50.21 to 81.99) |
| Confirmed Complete Response (CR) | 0.0 (0.00 to 9.49) |
| Confirmed Partial Response (PR) | 10.8 (3.03 to 25.42) |
| Confirmed Stable Disease (SD) ≥4 Months | 56.8 (39.49 to 72.90) |
| Without Clinical Benefit | 32.4 (NA to NA) |
Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. Clinical benefit in the central nervous system (CNS) was defined here as a complete response (CR), partial response (PR), or stable disease (SD) for at least 4 months, confirmed by repeat assessment according to RANO-BM criteria. Among participants who achieved clinical benefit, duration of clinical benefit in the CNS was defined as the time from documentation of the first CR, PR, or SD ≥4 months to the time of disease progression, relapse, or death from any cause. If a participant did not experience death or disease progression in the CNS before the end of the study, duration of clinical benefit was censored on the last date the participant was known to be progression free. Duration of clinical benefit was estimated by the Kaplan-Meier method.
| Months | Pertuzumab + Trastuzumab |
|---|---|
| Median Duration of Clinical Benefit (Confirmed CR, PR, or SD ≥4 Months) in the CNS, Assessed Using RANO-BM Criteria | 6.64 (3.2 to 56.1) |
Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. Clinical benefit in the central nervous system (CNS) was defined here as a complete response (CR), partial response (PR), or stable disease (SD) for at least 6 months, confirmed by repeat assessment according to RANO-BM criteria. A CR or PR were defined in the same way as for objective response in the CNS. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter (LD) while on study. The 95% Clopper-Pearson exact confidence intervals were calculated for responses.
| Percentage of Participants | Pertuzumab + Trastuzumab |
|---|---|
| With Clinical Benefit (Confirmed CR,PR,or SD≥6mos) | 51.4 (34.40 to 68.08) |
| Confirmed Complete Response (CR) | 0.0 (0.00 to 9.49) |
| Confirmed Partial Response (PR) | 10.8 (3.03 to 25.42) |
| Confirmed Stable Disease (SD) ≥6 Months | 40.5 (24.75 to 57.90) |
| Without Clinical Benefit | 48.6 (NA to NA) |
Responses were assessed by the investigator, based on magnetic resonance imaging (MRI) of the brain, physical examinations, routine neurological examinations, and corticosteroid dosing. Clinical benefit in the central nervous system (CNS) was defined here as a complete response (CR), partial response (PR), or stable disease (SD) for at least 6 months, confirmed by repeat assessment according to RANO-BM criteria. Among participants who achieved clinical benefit, duration of clinical benefit in the CNS was defined as the time from documentation of the first CR, PR, or SD ≥6 months to the time of disease progression, relapse, or death from any cause. If a participant did not experience death or disease progression in the CNS before the end of the study, duration of clinical benefit was censored on the last date the participant was known to be progression free. Duration of clinical benefit was estimated by the Kaplan-Meier method.
| Months | Pertuzumab + Trastuzumab |
|---|---|
| Median Duration of Clinical Benefit (Confirmed CR, PR, or SD ≥6 Months) in the CNS, Assessed Using RANO-BM Criteria | 9.23 (3.2 to 56.1) |
Progression-free survival (CNS) was defined as the time from the date of first dose to disease progression in the CNS or death from any cause. If no progressive disease in the CNS and no death occurred, progression-free survival (CNS) was censored on the date of the last CNS tumor assessment. If a post-baseline assessment was not available, progression-free survival (CNS) was censored on Day 1.
| Months | Pertuzumab + Trastuzumab |
|---|---|
| Progression-Free Survival (CNS), Assessed Using RANO-BM Criteria | 4.63 (0.82 to 56.11) |
Progression-free survival (systemic) was defined as the time from the date of first dose to systemic disease progression or death from any cause. If no systemic disease progression and no death occurred, progression-free survival (systemic) was censored on the date of the last systemic tumor assessment. If a post-baseline assessment was not available, progression-free survival (systemic) was censored on Day 1.
| Months | Pertuzumab + Trastuzumab |
|---|---|
| Progression-Free Survival (Systemic), Assessed Using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) | 16.26 (0.03 to 55.20) |
Progression-free survival (CNS or systemic) was defined as the time from the date of first dose to CNS or systemic disease progression or death from any cause. If no CNS or systemic disease progression and no death occurred, data was censored on the date of the last CNS or systemic tumor assessment, whichever occurred first. If a post-baseline assessment was not available, data was censored on Day 1.
| Months | Pertuzumab + Trastuzumab |
|---|---|
| Progression-Free Survival (CNS or Systemic), Assessed Using RANO-BM Criteria and RECIST v1.1 | 4.63 (0.03 to 55.20) |
Overall survival was defined as the period from the date of first dose until the date of death from any cause. If no death occurred, overall survival was censored on the last date the participant was known to be alive.
| Months | Pertuzumab + Trastuzumab |
|---|---|
| Overall Survival | 27.17 (0.82 to 57.49) |
| Participants | Pertuzumab + Trastuzumab |
|---|---|
| All Deaths | 20 |
| Deaths ≤30 Days From Last Dose of Study Drug | 1 |
| Deaths >30 Days From Last Dose of Study Drug | 19 |
| Primary Cause of Death: Progressive Disease | 16 |
| Primary Cause of Death: Other Cause (and Cancer) | 1 |
| Primary Cause of Death: Unknown | 3 |
Treatment-emergent adverse events (TEAEs) were defined as all adverse events occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment. All TEAEs were graded for severity using the NCI-CTCAE v4.0; any TEAE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to adverse event. Multiple occurrences of TEAEs were counted only once per participant at the highest (worst) grade.
| Participants | Pertuzumab + Trastuzumab |
|---|---|
| Any TEAE - Any Grade | 38 |
| Any TEAE - Grade 1 | 5 |
| Any TEAE - Grade 2 | 16 |
| Any TEAE - Grade 3 | 14 |
| Any TEAE - Grade 4 | 3 |
| Any TEAE - Grade 5 | 0 |
Treatment-emergent serious adverse events (SAEs) were defined as all adverse events that met seriousness criteria (as defined in the protocol; same as the ClinicalTrials.gov definition) occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment. All SAEs were graded for severity using the NCI-CTCAE v4.0; any SAE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe or medically significant, but not immediately life-threatening; Grade 4 = life-threatening consequences or urgent intervention indicated; and Grade 5 = death related to adverse event. The terms "severe" and "serious" are not synonymous and are independently assessed for each adverse event. Multiple occurrences of SAEs were counted only once per participant at the highest (worst) grade.
| Participants | Pertuzumab + Trastuzumab |
|---|---|
| Any SAE - Any Grade | 7 |
| Any SAE - Grade 1 | 0 |
| Any SAE - Grade 2 | 1 |
| Any SAE - Grade 3 | 5 |
| Any SAE - Grade 4 | 2 |
| Any SAE - Grade 5 | 0 |
Treatment-emergent adverse events (TEAEs) were defined as all adverse events occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment. All TEAEs were graded for severity using the NCI-CTCAE v4.0; any TEAE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to adverse event. Multiple occurrences of TEAEs were counted only once per participant at the highest (worst) grade.
| Participants | Pertuzumab + Trastuzumab |
|---|---|
| Withdrawal of Any Study Drug - Any Grade TEAE | 2 |
| Withdrawal of Any Study Drug - Grade 3 TEAE | 2 |
| Withdrawal of Pertuzumab Only - Any Grade TEAE | 0 |
| Withdrawal of Both Study Drugs - Any Grade TEAE | 2 |
| Withdrawal of Both Study Drugs - Grade 3 TEAE | 2 |
Treatment-emergent adverse events (TEAEs) were defined as all adverse events occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment. All TEAEs were graded for severity using the NCI-CTCAE v4.0; any TEAE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to adverse event. Multiple occurrences of TEAEs were counted only once per participant at the highest (worst) grade.
| Participants | Pertuzumab + Trastuzumab |
|---|---|
| Any TEAE - Any Grade | 7 |
| Any TEAE - Grade 1 | 1 |
| Any TEAE - Grade 2 | 4 |
| Any TEAE - Grade 3 | 1 |
| Any TEAE - Grade 4 | 1 |
| Any TEAE - Grade 5 | 0 |
Treatment-emergent adverse events (TEAEs) were defined as all adverse events occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment. All TEAEs were graded for severity using the NCI-CTCAE v4.0; any TEAE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to adverse event. Multiple occurrences of TEAEs were counted only once per participant at the highest (worst) grade.
| Participants | Pertuzumab + Trastuzumab |
|---|---|
| Any TEAE - Any Grade | 12 |
| Any TEAE - Grade 1 | 2 |
| Any TEAE - Grade 2 | 4 |
| Any TEAE - Grade 3 | 5 |
| Any TEAE - Grade 4 | 1 |
| Any TEAE - Grade 5 | 0 |
Protocol-defined TEAEs of special interest, occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment, included the following: An elevated ALT or AST (\>3 times baseline value) in combination with either an elevated total bilirubin (\>2 times the upper limit of normal) or clinical jaundice; Suspected transmission of an infectious agent by the study treatment; Congestive heart failure; An asymptomatic decline in LVEF (a value 10 percentage points below baseline or lower, and \<45%) that requires treatment or that leads to discontinuation of study treatment. All TEAEs of special interest were graded for severity using the NCI-CTCAE v4.0. Multiple occurrences of TEAEs of special interest were counted only once per participant at the highest (worst) grade.
| Percentage of Participants | Pertuzumab + Trastuzumab |
|---|---|
| Any TEAE of Special Interest - Any Grade | 2.6 (0.06 to 13.48) |
| Asymptomatic Decline in LVEF - Grade 3 | 2.6 (0.06 to 13.48) |
Left ventricular ejection fraction (LVEF) is the measurement of the percentage of blood that is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. All participants were required to have had a baseline LVEF of at least 50% to participate in this study. Measurements were done by either echocardiogram (ECHO) or mulitple-gated acquisition (MUGA) scan (with ECHO as the preferred method). Participants were to be reassessed with the same technique used for baseline cardiac evaluation throughout the study.
| Percentage Points of LVEF (%) | Pertuzumab + Trastuzumab |
|---|---|
| Baseline | 60.00 (50.00 to 75.00) |
| Week 6 | 60.00 (30.00 to 69.00) |
| Week 12 | 60.00 (51.00 to 73.00) |
| Week 24 | 60.00 (50.00 to 67.00) |
| Week 36 | 60.00 (50.00 to 65.00) |
| Week 48 | 60.00 (48.00 to 64.00) |
| Week 60 | 62.00 (49.00 to 70.00) |
| Week 72 | 55.50 (53.00 to 65.00) |
| Week 84 | 60.00 (55.00 to 62.00) |
| Week 96 | 63.00 (60.00 to 65.00) |
| Week 108 | 62.00 (60.00 to 64.00) |
| Week 120 | 64.00 (64.00 to 64.00) |
| Week 132 | 64.00 (64.00 to 64.00) |
| Survival Follow-Up 1 | 60.00 (50.00 to 68.00) |
| Survival Follow-Up 2 | 59.00 (53.00 to 75.00) |
| Survival Follow-Up 3 | 60.00 (55.00 to 65.00) |
| Survival Follow-Up 4 | 69.00 (66.00 to 72.00) |
| Survival Follow-Up 5 | 67.00 (60.00 to 72.00) |
| Survival Follow-Up 6 | 57.00 (55.00 to 58.00) |
| Survival Follow-Up 7 | 57.50 (55.00 to 60.00) |
| Survival Follow-Up 8 | 57.00 (55.00 to 59.00) |
Left ventricular ejection fraction (LVEF) is the measurement of the percentage of blood that is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. All participants were required to have had a baseline LVEF of at least (≥)50% to participate in this study. Measurements were done by either echocardiogram (ECHO) or mulitple-gated acquisition (MUGA) scan (with ECHO as the preferred method). Participants were to be reassessed with the same technique used for baseline cardiac evaluation throughout the study. The following are definitions for the three categories of LVEF findings: 'Normal' was defined as LVEF \>45% or LVEF 40-45% with less than (\<)10% points drop below baseline; 'Abnormal' was defined as LVEF \<40% or LVEF ≥10% points drop below baseline, and clinically significant versus non-clinically significant was subject to the investigator's assessment of whether symptoms were present or absent.
| Participants | Pertuzumab + Trastuzumab |
|---|---|
| Baseline — Normal | 39 |
| Baseline — Abnormal, Not Clinically Significant | 0 |
| Baseline — Abnormal, Clinically Significant | 0 |
| Week 6 — Normal | 33 |
| Week 6 — Abnormal, Not Clinically Significant | 0 |
| Week 6 — Abnormal, Clinically Significant | 1 |
| Week 12 — Normal | 30 |
| Week 12 — Abnormal, Not Clinically Significant | 0 |
| Week 12 — Abnormal, Clinically Significant | 0 |
| Week 24 — Normal | 14 |
| Week 24 — Abnormal, Not Clinically Significant | 1 |
| Week 24 — Abnormal, Clinically Significant | 0 |
| Week 36 — Normal | 9 |
| Week 36 — Abnormal, Not Clinically Significant | 0 |
| Week 36 — Abnormal, Clinically Significant | 0 |
| Week 48 — Normal | 6 |
| Week 48 — Abnormal, Not Clinically Significant | 1 |
| Week 48 — Abnormal, Clinically Significant | 0 |
| Week 60 — Normal | 6 |
| Week 60 — Abnormal, Not Clinically Significant | 1 |
| Week 60 — Abnormal, Clinically Significant | 0 |
| Week 72 — Normal | 4 |
| Week 72 — Abnormal, Not Clinically Significant | 0 |
| Week 72 — Abnormal, Clinically Significant | 0 |
| Week 84 — Normal | 3 |
| Week 84 — Abnormal, Not Clinically Significant | 0 |
| Week 84 — Abnormal, Clinically Significant | 0 |
| Week 96 — Normal | 3 |
| Week 96 — Abnormal, Not Clinically Significant | 0 |
| Week 96 — Abnormal, Clinically Significant | 0 |
| Week 108 — Normal | 2 |
| Week 108 — Abnormal, Not Clinically Significant | 0 |
| Week 108 — Abnormal, Clinically Significant | 0 |
| Week 120 — Normal | 1 |
| Week 120 — Abnormal, Not Clinically Significant | 0 |
| Week 120 — Abnormal, Clinically Significant | 0 |
| Week 132 — Normal | 1 |
| Week 132 — Abnormal, Not Clinically Significant | 0 |
| Week 132 — Abnormal, Clinically Significant | 0 |
| Survival Follow-Up 1 — Normal | 5 |
| Survival Follow-Up 1 — Abnormal, Not Clinically Significant | 0 |
| Survival Follow-Up 1 — Abnormal, Clinically Significant | 0 |
| Survival Follow-Up 2 — Normal | 12 |
| Survival Follow-Up 2 — Abnormal, Not Clinically Significant | 0 |
| Survival Follow-Up 2 — Abnormal, Clinically Significant | 0 |
| Survival Follow-Up 3 — Normal | 5 |
| Survival Follow-Up 3 — Abnormal, Not Clinically Significant | 0 |
| Survival Follow-Up 3 — Abnormal, Clinically Significant | 0 |
| Survival Follow-Up 4 — Normal | 1 |
| Survival Follow-Up 4 — Abnormal, Not Clinically Significant | 1 |
| Survival Follow-Up 4 — Abnormal, Clinically Significant | 0 |
| Survival Follow-Up 5 — Normal | 3 |
| Survival Follow-Up 5 — Abnormal, Not Clinically Significant | 0 |
| Survival Follow-Up 5 — Abnormal, Clinically Significant | 0 |
| Survival Follow-Up 6 — Normal | 3 |
| Survival Follow-Up 6 — Abnormal, Not Clinically Significant | 0 |
| Survival Follow-Up 6 — Abnormal, Clinically Significant | 0 |
| Survival Follow-Up 7 — Normal | 2 |
| Survival Follow-Up 7 — Abnormal, Not Clinically Significant | 0 |
| Survival Follow-Up 7 — Abnormal, Clinically Significant | 0 |
| Survival Follow-Up 8 — Normal | 2 |
| Survival Follow-Up 8 — Abnormal, Not Clinically Significant | 0 |
| Survival Follow-Up 8 — Abnormal, Clinically Significant | 0 |
Clinical laboratory tests for hematology parameters were performed every 6 weeks and any abnormal values (High or Low) were based on NCI-CTCAE v4.0 grades. Laboratory abnormalities of NCI-CTCAE v4.0 Grades 3 and 4 are presented. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. For the overall category, multiple occurrences of the same laboratory abnormality over time in one participant were only counted once.
| Participants | Pertuzumab + Trastuzumab |
|---|---|
| Overall: Lymphocytes (10^9/L), Low - Grade 3 | 3 |
| Overall: Lymphocytes (10^9/L), High - Grade 3 | 0 |
| Overall: Lymphocytes (10^9/L), Low - Grade 4 | 1 |
| Overall: Lymphocytes (10^9/L), High - Grade 4 | 0 |
| Baseline: Lymphocytes (10^9/L), Low - Grade 3 | 2 |
| Baseline: Lymphocytes (10^9/L), Low - Grade 4 | 0 |
| Week 18: Lymphocytes (10^9/L), Low - Grade 3 | 1 |
| Week 18: Lymphocytes (10^9/L), Low - Grade 4 | 0 |
| Week 36: Lymphocytes (10^9/L), Low - Grade 3 | 1 |
| Week 36: Lymphocytes (10^9/L), Low - Grade 4 | 0 |
| Week 60: Lymphocytes (10^9/L), Low - Grade 3 | 0 |
| Week 60: Lymphocytes (10^9/L), Low - Grade 4 | 1 |
Clinical laboratory tests for blood chemistry parameters were performed every 6 weeks and any abnormal values (High or Low) were based on NCI-CTCAE v4.0 grades. Laboratory abnormalities of NCI-CTCAE v4.0 Grades 3 and 4 are presented. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. For the overall category, multiple occurrences of the same laboratory abnormality over time in one participant were only counted once.
| Participants | Pertuzumab + Trastuzumab |
|---|---|
| Overall: Glucose (mmol/L), Low - Grade 3 | 0 |
| Overall: Glucose (mmol/L), High - Grade 3 | 2 |
| Overall: Glucose (mmol/L), Low - Grade 4 | 0 |
| Overall: Glucose (mmol/L), High - Grade 4 | 0 |
| Week 6: Glucose (mmol/L), High - Grade 3 | 1 |
| Week 12: Glucose (mmol/L), High - Grade 3 | 1 |
| Week 18: Glucose (mmol/L), High - Grade 3 | 1 |
| Overall: Potassium (mmol/L), Low - Grade 3 | 0 |
| Overall: Potassium (mmol/L), High - Grade 3 | 0 |
| Overall: Potassium (mmol/L), Low - Grade 4 | 1 |
| Overall: Potassium (mmol/L), High - Grade 4 | 0 |
| Unscheduled Visit: Potassium (mmol/L),Low -Grade 4 | 1 |
Per protocol eligibility criteria, participants were not required to be pertuzumab naïve; therefore pertuzumab was detectable in some participants pre-dose at Week 1.
| micrograms per millilitre (ug/mL) | Pertuzumab + Trastuzumab |
|---|---|
| Week 1 Day 1 | 43.12 ± 101.45 |
| Week 4 Day 1 | 88.03 ± 29.91 |
| Week 10 Day 1 | 94.46 ± 38.47 |
| Week 16 Day 1 | 101.99 ± 41.59 |
| micrograms per millilitre (ug/mL) | Pertuzumab + Trastuzumab |
|---|---|
| Week 1 Day 1 | 275.94 ± 88.80 |
| Week 16 Day 1 | 225.55 ± 56.22 |
Per protocol eligibility criteria, participants were not required to be trastuzumab naïve; therefore trastuzumab was detectable in some participants pre-dose at Week 1.
| micrograms per millilitre (ug/mL) | Pertuzumab + Trastuzumab |
|---|---|
| Week 1 Day 1 | 57.00 ± 52.73 |
| Week 4 Day 1 | 190.82 ± 52.22 |
| Week 10 Day 1 | 294.50 ± 70.33 |
| Week 16 Day 1 | 306.14 ± 90.22 |
| micrograms per millilitre (ug/mL) | Pertuzumab + Trastuzumab |
|---|---|
| Week 1 Day 1 | 181.43 ± 72.49 |
| Week 16 Day 1 | 394.14 ± 94.09 |
The MDASI-BT consists of 28 items and is a multi-symptom measure of cancer-related symptoms (Cleeland et al. 2000) that are sensitive to disease and treatment changes. The MDASI-BT is composed of the symptom severity scale and the symptom interference scale. In the symptom severity scale, participants rate the severity of their symptoms in the last 24 hours on 0-10 numeric scales, ranging from 0 = "not present" to 10 = "as bad as you can imagine." The MDASI-BT symptom severity scale score will be calculated by (sum of total scores of non-missing items) divided by (total number of non-missing items), if participants answered at least 12 of the 22 severity scale items. The score will be considered missing if less than 12 items are completed.
| Score on a scale | Pertuzumab + Trastuzumab |
|---|---|
| Baseline | 1.65 ± 1.618 |
| Week 6 | 1.97 ± 1.822 |
| Week 12 | 2.24 ± 2.141 |
| Week 20 | 2.09 ± 2.111 |
| Week 28 | 1.94 ± 2.547 |
| Week 40 | 2.78 ± 2.856 |
| Week 52 | 3.53 ± 3.018 |
| Week 64 | 3.12 ± 2.500 |
The MDASI-BT consists of 28 items and is a multi-symptom measure of cancer-related symptoms that are sensitive to disease and treatment changes. The MDASI-BT is composed of the symptom severity scale and the symptom interference scale. In the symptom interference scale, participants rate interference with daily activities caused by their symptoms on 0-10 numeric scales ranging from 0 = "did not interfere" to 10 = "interfered completely." The MDASI-BT symptom interference scale score will be calculated by (sum of total scores of non-missing items) divided by (total number of non-missing items), if participants answered at least 4 of the 6 interference scale items. The score will be considered missing if less than 4 items are completed.
| Score on a scale | Pertuzumab + Trastuzumab |
|---|---|
| Baseline | 2.51 ± 2.629 |
| Week 6 | 2.23 ± 2.787 |
| Week 12 | 2.81 ± 3.391 |
| Week 20 | 2.11 ± 2.858 |
| Week 28 | 1.76 ± 2.427 |
| Week 40 | 3.24 ± 3.548 |
| Week 52 | 4.25 ± 3.522 |
| Week 64 | 3.93 ± 3.570 |
Collected over From first dose of study drug until 30 days after last dose of study drug (except for serious AEs related to treatment; up to approximately 5 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pertuzumab + Trastuzumab | 20/39 (51.3%) | 7/39 (17.9%) | 38/39 (97.4%) |
| Event | Pertuzumab + Trastuzumab |
|---|---|
| SeizureNervous system disorders | 4/39 |
| Gastroenteritis viralInfections and infestations | 1/39 |
| Parainfluenzae virus infectionInfections and infestations | 1/39 |
| HeadacheNervous system disorders | 1/39 |
| HydrocephalusNervous system disorders | 1/39 |
| HypertensionVascular disorders | 1/39 |
| Event | Pertuzumab + Trastuzumab |
|---|---|
| DiarrhoeaGastrointestinal disorders | 23/39 |
| FatigueGeneral disorders | 17/39 |
| NauseaGastrointestinal disorders | 12/39 |
| VomitingGastrointestinal disorders | 12/39 |
| ConstipationGastrointestinal disorders | 7/39 |
| DizzinessNervous system disorders | 7/39 |
| InsomniaPsychiatric disorders | 7/39 |
| AstheniaGeneral disorders | 6/39 |
| Upper respiratory tract infectionInfections and infestations | 6/39 |
| Decreased appetiteMetabolism and nutrition disorders | 6/39 |
Intent-to-Treat (ITT) population: all enrolled patients in the study, regardless of whether they were exposed to study treatment.
| Age, Continuous(Years) | Pertuzumab + Trastuzumab |
|---|---|
| Mean | 50.0 ± 9.78 |
| Sex: Female, Male(Participants) | Pertuzumab + Trastuzumab |
|---|---|
| Female | 40 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | Pertuzumab + Trastuzumab |
|---|---|
| Hispanic or Latino | 6 |
| Not Hispanic or Latino | 33 |
| Unknown or Not Reported | 1 |
| Race/Ethnicity, Customized(Participants) | Pertuzumab + Trastuzumab |
|---|---|
| White | 36 |
| Asian | 2 |
| Other Race | 1 |
| Not Reported | 1 |
| Women of Childbearing Potential Status(Participants) | Pertuzumab + Trastuzumab |
|---|---|
| Childbearing Potential | 12 |
| Non-Childbearing Potential - Postmenopausal | 21 |
| Non-Childbearing Potential - Surgically Sterile | 7 |
| Left Ventricular Ejection Fraction (LVEF) Value at Baseline(Percentage Points of LVEF (%)) | Pertuzumab + Trastuzumab |
|---|---|
| Median | 60.00 (50.00 to 75.00) |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2015 to primary completion in May 2019, 40 months.
Results were first posted in Mar 2020, 10 months after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 40 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pertuzumab · Trastuzumab